Similar findings were noted in two additional patients with neuroendocrine transformation of EGFR mutant lung adenocarcinoma following treatment with EGFR inhibitors, both of whom showed reduced MHC-I staining in the transformed SCLC (Figure S6D). Here, EGFR is linked to lung adenocarcinoma.